PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportscentral nervous system neoplasms
MeSH D016543 - central nervous system neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009423:Nervous system neoplasms
1 Company
1 Drug
$
Success rate
D016543: 
Central nervous system neoplasms
17 Companies
1 Drug
$
Success rate
D001932:Brain neoplasms
93 Companies
20 Drugs
$
Success rate
D008577:Meningeal neoplasms
14 Companies
3 Drugs
$
Success rate
D013120:Spinal cord neoplasms
30 Companies
1 Drug
$
Success rate
D020863:Central nervous system cysts
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCarboplatin Carboplatin  2005-09-21   
Novast LaboratoriesCarboplatin Carboplatin  2017-04-26   
MylanCarboplatin Carboplatin  2007-04-24   
NATCO PharmaCarboplatin Carboplatin  2012-05-29   
CiplaCarboplatin Carboplatin  2006-01-27   
SandozCarboplatin Carboplatin  2005-03-18   
Sun Pharmaceutical IndustriesCarboplatin Carboplatin  2008-09-19   
HospiraCarboplatin Carboplatin  2004-10-27   
Accord HealthcareCarboplatin Carboplatin  2017-02-09   
Hikma PharmaceuticalsCarboplatin Carboplatin  2004-10-14   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
61%
86/140
Phase 2
22%
30/137
Phase 3
5%
2/40
Approved: 1Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Carboplatin
Mylan
Carboplatin
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use